-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SLJk328I/eciAtjIrP6g7waIL2FRDbK2DA49MxmUUAzrH0PaD50UeyE0y/RBjPye tHFzNXtqOLvt3F5ra6WWFw== 0001275287-05-001337.txt : 20050420 0001275287-05-001337.hdr.sgml : 20050420 20050420060607 ACCESSION NUMBER: 0001275287-05-001337 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050420 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050420 DATE AS OF CHANGE: 20050420 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSGENOMIC INC CENTRAL INDEX KEY: 0001043961 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 911789357 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30975 FILM NUMBER: 05760526 BUSINESS ADDRESS: STREET 1: 12325 EMMET ST CITY: OMAHA STATE: NE ZIP: 68164 BUSINESS PHONE: 4027385480 MAIL ADDRESS: STREET 1: 12325 EMMET STREET CITY: OMAHA STATE: NE ZIP: 68164 8-K 1 ti2450.txt ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2005 TRANSGENOMIC, INC. (Exact name of registrant as specified in its charter) Delaware 000-30975 (State of Formation) (Commission File Number) 911789357 (IRS Employer Identification Number) 12325 Emmet Street Omaha, NE 68164 (Address of principal executive offices) (Zip Code) (402) 452-5400 (Registrants' telephone number, including area code) Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e(c)) ================================================================================ ITEM 8.01 OTHER EVENTS. On Wednesday, April 20, 2005, the Company issued a press release announcing it has agreed to provide additional quantities of modified nucleic acid building block compounds to Geron Corporation under terms of a new addendum to an existing Master Supply Agreement between the two companies. A copy of the press release is filed herewith as Item 9.01 and is incorporated herein by reference. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. Press Release, dated April 20, 2005, announcing that the Company has agreed to provide additional quantities of modified nucleic acid building block compounds to Geron Corporation under terms of a new addendum to an existing Master Supply Agreement between the two companies. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRANSGENOMIC, INC. By /s/ Mitchell L. Murphy --------------------------- Michael Summers VP, Secretary & Treasurer April 20, 2005 3 EX-99.1 2 ti2450ex991.txt Exhibit 99.1 TRANSGENOMIC INC. CONTINUES TO PROVIDE SPECIALTY NUCLEIC ACID PRODUCTS TO GERON CORPORATION ONGOING SUPPORT FOR MANUFACTURE OF GERON'S NOVEL CANCER THERAPEUTIC OMAHA, Neb., April 20 /PRNewswire-FirstCall/ -- Transgenomic Inc. (Nasdaq: TBIO) announced today it has agreed to provide additional quantities of modified nucleic acid building block compounds to Geron Corporation (Nasdaq: GERN) under terms of a new addendum to an existing Master Supply Agreement between the two companies. The compounds will be used in the synthesis of Geron's anti-cancer drug GRN163L. GRN163L is a thio- phosphoramidate oligonucleotide, a class of synthetic nucleic acid that has a number of potential advantages over earlier-generation synthetic nucleic acid chemistries, including enhanced sequence-specific DNA and RNA binding activity, high resistance to degradation, and improved uptake and biodistribution properties. Product shipments under the new addendum will be completed in the second half of 2005. "We are pleased to have the opportunity to provide ongoing manufacturing support to Geron as they continue to develop their novel cancer therapeutics," said Collin D'Silva, Transgenomic's CEO. D'Silva continued, "We have sharpened our nucleic acid building block manufacturing operation's focus on supporting the manufacture of innovative, next-generation synthetic nucleic acids, a market segment in which we have a significant competitive edge." About Transgenomic Transgenomic provides versatile and innovative research tools and related consumable products. Transgenomic's BioSystems segment offers its WAVE(R) Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. These systems have broad applicability to genetic research and molecular diagnostics. To date there have been approximately one thousand systems installed in over 30 countries around the world. In addition, the BioSystems segment offers WAVE-based biomarker discovery and validation services in support of translational research, pre-clinical and clinical studies. Through its Nucleic Acids business segment, Transgenomic provides specialty chemicals, including advanced nucleic acid building blocks and associated reagents used in the manufacture of synthetic oligonucleotides. For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company's Web site at www.transgenomic.com. Forward-Looking Statement Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including claims of significant competitive edge in certain market segments. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law. SOURCE Transgenomic Inc. -0- 04/20/2005 /CONTACT: Mitchell L. Murphy, +1-402-452-5418, mmurphy@transgenomic.com, or Robert J. Pogulis, Ph.D., +1-845-782-9617, rpogulis@transgenomic.com, both of Transgenomic, Inc./ /Web site: http://www.transgenomic.com / - - -----END PRIVACY-ENHANCED MESSAGE-----